Antibody–drug conjugates (ADCs) represent a promising class of biopharmaceuticals with
the potential to localize at the tumor site and improve the therapeutic index of cytotoxic drugs. …

We describe the cloning and characterization of a novel fusion protein (termed L19‐mIL12),
consisting of murine interleukin‐12 in single‐chain format, sequentially fused to the L19 …

Purpose: There is a growing interest in the use of tumor antigens for therapeutic vaccination
strategies. Unfortunately, in most cases, the use of peptide vaccines in patients does not …

Mice bearing CT26 tumors can be cured by administration of L19‐mIL12 or F8‐mTNF, two
antibody fusion proteins which selectively deliver their cytokine payload to the tumor. In both …

Engineered cytokines are gaining importance in cancer therapy, but these products are often
limited by toxicity, especially at early time points after intravenous administration. 4-1BB is …

IL15 is an immunostimulatory cytokine that holds promises for cancer therapy, but its
performance (alone or as partner for fusion proteins) has often been limited by suboptimal …

Antibody–cytokine fusion proteins can have the potential to increase the density and activity
of subsets of leukocytes within the tumor mass. Here, we describe the design, production, …

The targeted delivery of interleukin-2 to the tumor is gaining attention as an avenue to
potentiate the action of T and NK cells at the site of disease. We have previously described the …

There is a growing interest in the use of patient-derived T cells for the treatment of various
types of malignancies. The expansion of a polyclonal and polyspecific population of tumor-…

The recombinant murine IgG2a antibody TA99, directed against a melanoma antigen, was
used to study combination modalities that potentiate antibody-dependent cell cytotoxicity. As …